Moody’s downgrades Senegal to Caa1 amid rising debt concerns
PARSIPPANY, N.J. - Animal health company Zoetis Inc. (NYSE:ZTS) announced Thursday that its Board of Directors has declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025. The company has maintained an impressive track record of raising dividends for 12 consecutive years, with a 15.7% dividend growth over the last twelve months.
The dividend will be paid on Tuesday, December 2, 2025, to shareholders of record as of the close of business on Friday, October 31, 2025.
Zoetis, which describes itself as the world’s leading animal health company, focuses on developing medicines, vaccines, diagnostics and technologies for animals. The Fortune 500 company generated revenue of $9.3 billion in 2024 and employs approximately 13,800 people globally.
The company operates in over 100 countries and has been in the animal health business for more than 70 years, according to the press release statement.
Zoetis provides products and services for both livestock producers and pet owners, as well as veterinarians, maintaining a portfolio of animal health solutions.
In other recent news, Zoetis Inc. announced that its Dectomax-CA1 Injectable has received conditional approval from the U.S. Food and Drug Administration for the prevention and treatment of New World screwworm infestations in cattle. This approval marks the first of its kind in the U.S., providing up to 21 days of protection against reinfestation. Additionally, the European Medicines Agency’s Committee for Veterinary Medicinal Products has given a positive opinion recommending marketing authorization for Zoetis’s Portela, a treatment for osteoarthritis pain in cats. In financial developments, Zoetis has entered into a new five-year, $1.25 billion revolving credit facility with a syndicate of banks, replacing a prior agreement. Moreover, Zoetis disclosed an issuance of $1.85 billion in senior notes, with maturities set for 2028 and 2035, further strengthening its financial position. These recent developments reflect Zoetis’s ongoing efforts in both product innovation and financial management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.